AB&B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine

Reuters

09/03

AB&B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine

AB&B Bio-Tech Co. Ltd. JS has received regulatory approval from the National Medical Products Administration (NMPA) of the People's Republic of China for its new quadrivalent subunit influenza vaccine. This vaccine, designed for individuals aged 6 to 35 months, represents the first and only quadrivalent subunit influenza vaccine approved in China for all age groups at full dosage level. The product offers comprehensive protection, high antigen purity, and low risks of adverse reactions. The company, focused on innovative vaccine development, aims to replace traditional and imported vaccines in China and expand into international markets. Shareholders and potential investors are advised to exercise caution when dealing with the company's securities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564643483"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564643483\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564643483?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 17:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564643483","market":"fut","top_or_hot":-1,"title":"AB&B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AB&amp;B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AB&amp;B Bio-Tech Co. Ltd. JS has received regulatory approval from the National Medical Products Administration (NMPA) of the People's Republic of China for its new quadrivalent subunit influenza vaccine. This vaccine, designed for individuals aged 6 to 35 months, represents the first and only quadrivalent subunit influenza vaccine approved in China for all age groups at full dosage level. The product offers comprehensive protection, high antigen purity, and low risks of adverse reactions. The company, focused on innovative vaccine development, aims to replace traditional and imported vaccines in China and expand into international markets. Shareholders and potential investors are advised to exercise caution when dealing with the company's securities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&amp;B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AB&B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAB&B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-03 17:59</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AB&amp;B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AB&amp;B Bio-Tech Co. Ltd. JS has received regulatory approval from the National Medical Products Administration (NMPA) of the People's Republic of China for its new quadrivalent subunit influenza vaccine. This vaccine, designed for individuals aged 6 to 35 months, represents the first and only quadrivalent subunit influenza vaccine approved in China for all age groups at full dosage level. The product offers comprehensive protection, high antigen purity, and low risks of adverse reactions. The company, focused on innovative vaccine development, aims to replace traditional and imported vaccines in China and expand into international markets. Shareholders and potential investors are advised to exercise caution when dealing with the company's securities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&amp;B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02627","symbol_name":"中慧生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDL8mynwc:1","article_id":"2564643483","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564643483","pubTimestamp":1756893552,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AB&B Bio-Tech Co. Ltd. JS has received regulatory approval from the National Medical Products Administration  of the People's Republic of China for its new quadrivalent subunit influenza vaccine. This vaccine, designed for individuals aged 6 to 35 months, represents the first and only quadrivalent subunit influenza vaccine approved in China for all age groups at full dosage level. The product offers comprehensive protection, high antigen purity, and low risks of adverse reactions. The company, focused on innovative vaccine development, aims to replace traditional and imported vaccines in China and expand into international markets. Shareholders and potential investors are advised to exercise caution when dealing with the company's securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02627":"中慧生物-B","BK1161":"生物科技"},"translate_title":"AB&B Bio-Tech Co.Ltd.JS获得NMPA批准中国首个四价亚单位流感疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02627":0.9},"content_text":"AB&B Bio-Tech Co. Ltd. JS Secures NMPA Approval for China's First Quadrivalent Subunit Influenza Vaccine\n    \n\n        AB&B Bio-Tech Co. Ltd. JS has received regulatory approval from the National Medical Products Administration (NMPA) of the People's Republic of China for its new quadrivalent subunit influenza vaccine. This vaccine, designed for individuals aged 6 to 35 months, represents the first and only quadrivalent subunit influenza vaccine approved in China for all age groups at full dosage level. The product offers comprehensive protection, high antigen purity, and low risks of adverse reactions. The company, focused on innovative vaccine development, aims to replace traditional and imported vaccines in China and expand into international markets. Shareholders and potential investors are advised to exercise caution when dealing with the company's securities.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}